What question did this study set out to answer?

The study aimed to evaluate the impact of buprenorphine on reducing full agonist opioid exposure and improving sedation during ECMO support.

June 13, 2026

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case‐Control Study

Key Points

The study aimed to evaluate the impact of buprenorphine on reducing full agonist opioid exposure and improving sedation during ECMO support.
Retrospective matched case-control cohort design among ECMO patients in a cardiovascular ICU.
Compared 30 patients treated with buprenorphine to 30 matched controls not receiving buprenorphine.
Primary outcome measured was the difference in daily intravenous morphine milligram equivalents (MME) between groups.
Buprenorphine cohort showed a significant decrease in MME from 184.1 to 0.0 (p < 0.001), while NO-BUP cohort decreased non-significantly from 230.8 to 177.2 (p = 0.517).
Significant improvement in target RASS range for the BUP group from 53.9% to 91.2% (p < 0.001) compared to NO-BUP group (37.8% to 46.1%, p = 0.275).
No incidents of precipitated withdrawal or respiratory depression were noted in the BUP cohort.

Abstract

INTRODUCTION: Patients supported with extracorporeal membrane oxygenation (ECMO) frequently require prolonged, high-intensity analgosedation because of neuromuscular blockade, pain related to procedures, and pharmacokinetic alterations. These exposures increase the risk of iatrogenic medication toxicity and withdrawal. OBJECTIVES: We evaluated whether buprenorphine (BUP) use during ECMO reduced full agonist opioid exposure and improved sedation compared with matched comparators. METHODS: Using a retrospective matched case-control cohort design among ECMO patients in a cardiovascular intensive care unit, we contrasted 30 patients treated with BUP versus 30 comparator patients not treated with BUP (NO-BUP) matched using an a priori deterministic hierarchy. Comparisons were anchored to two matched time points: (i) the day before BUP exposure and (ii) the day after attaining the full therapeutic BUP dose; NO-BUP comparators were assessed on the analogous ECMO days. The primary outcome was the between-group difference in change in daily intravenous morphine milligram equivalents (MME) across this time period. RESULTS: Each cohort included 27 venovenous and three venoarterial ECMO patients. Demographics and illness severity did not differ between groups. Groups significantly differed in MME change scores (p < 0.001) with the BUP cohort decreasing significantly (p < 0.001) from 184.1 (interquartile range IQR 70.2-367.2) to 0.0 (IQR 0.0-11.6) median MME whereas NO-BUP comparators nonsignificantly decreased (p = 0.517) from 230.8 (IQR 153.3-567.0) to 177.2 (IQR 85.3-663.1). Groups also differed (p = 0.031) in time in target RASS range (-2 to 0); the BUP cohort significantly improved from 53.9% to 91.2% (p < 0.001) whereas NO-BUP comparators nominally improved from 37.8% to 46.1% (p = 0.275). In the BUP cohort, there was no precipitated withdrawal, opioid-induced constipation, or respiratory depression. Rates of tracheostomy, mortality, and extubation before decannulation did not differ significantly. CONCLUSION: BUP initiation among ECMO patients was feasible and associated with a marked reduction in full agonist opioid exposure and improved light-sedation target attainment. These findings are hypothesis-generating given the retrospective design and potential residual confounding.

Mark Helpful

Bookmark

Relay